Perspective wins EU orphan drug designation for [²¹²Pb]VMT-α-NET in GEP-NETs

The European Commission decision could bring protocol assistance, fee reductions and up to 10 years of market exclusivity if the radiopharmaceutical is approved.

Summary

verifying reliability

Terms & Concepts

No specialized terms available for this topic.